David Q-H Wang

List of Publications by Year
in descending order

116 papers	6,346 citations	47 h-index	75 g-index
		47006	74163
118 all docs	118 docs citations	118 times ranked	5842 citing authors

#	Article	IF	Citations
1	Overcoming Ductal Block: Emergency ERCP and Sphincterotomy Plus Common Bile Duct Stenting Improves Therapeutic Outcomes in Severe Gallstone Pancreatitis. Digestive Diseases and Sciences, 2022, 67, 11-13.	2.3	1
2	Impact of Sequential Lipid Meals on Lymphatic Lipid Absorption and Transport in Rats. Genes, 2022, 13, 277.	2.4	1
3	Gut Microbiota and Short Chain Fatty Acids: Implications in Glucose Homeostasis. International Journal of Molecular Sciences, 2022, 23, 1105.	4.1	215
4	Intestinal Barrier and Permeability in Health, Obesity and NAFLD. Biomedicines, 2022, 10, 83.	3.2	71
5	Genetic Analysis of ABCB4 Mutations and Variants Related to the Pathogenesis and Pathophysiology of Low Phospholipid-Associated Cholelithiasis. Genes, 2022, 13, 1047.	2.4	10
6	Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB/c.Abcb4 mouse model of PFIC3. Journal of Hepatology, 2021, 74, 1416-1428.	3.7	34
7	Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?. International Journal of Molecular Sciences, 2021, 22, 5375.	4.1	59
8	Mitochondria Matter: Systemic Aspects of Nonalcoholic Fatty Liver Disease (NAFLD) and Diagnostic Assessment of Liver Function by Stable Isotope Dynamic Breath Tests. International Journal of Molecular Sciences, 2021, 22, 7702.	4.1	18
9	Hepatocyte miR-34a is a key regulator in the development and progression of non-alcoholic fatty liver disease. Molecular Metabolism, 2021, 51, 101244.	6.5	35
10	Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD). Methods in Molecular Biology, 2021, 2310, 201-246.	0.9	11
11	Emerging Trends in Deciphering the Pathogenesis of Human Diseases through Genetic Analysis. Genes, 2021, 12, 96.	2.4	1
12	Regulation of Cholesterol Metabolism by Bioactive Components of Soy Proteins: Novel Translational Evidence. International Journal of Molecular Sciences, 2021, 22, 227.	4.1	27
13	Sexual dimorphism in intestinal absorption and lymphatic transport of dietary lipids. Journal of Physiology, 2021, 599, 5015-5030.	2.9	7
14	Bile Formation and Pathophysiology of Gallstones. , 2020, , 287-306.		5
15	G Protein-Coupled Estrogen Receptor, GPER1, Offers a Novel Target for the Treatment of Digestive Diseases. Frontiers in Endocrinology, 2020, 11, 578536.	3.5	15
16	An Update on the Lithogenic Mechanisms of Cholecystokinin a Receptor (CCKAR), an Important Gallstone Gene for Lith13. Genes, 2020, 11, 1438.	2.4	10
17	Bile Acids and GPBAR-1: Dynamic Interaction Involving Genes, Environment and Gut Microbiome. Nutrients, 2020, 12, 3709.	4.1	28
18	Liver Steatosis, Gut-Liver Axis, Microbiome and Environmental Factors. A Never-Ending Bidirectional Cross-Talk. Journal of Clinical Medicine, 2020, 9, 2648.	2.4	93

#	Article	IF	Citations
19	Gut Microbiota between Environment and Genetic Background in Familial Mediterranean Fever (FMF). Genes, 2020, 11, 1041.	2.4	16
20	Estradiol Enhances Anorectic Effect of Apolipoprotein A-IV through ERÎ±-PI3K Pathway in the Nucleus Tractus Solitarius. Genes, 2020, 11, 1494.	2.4	3
21	Differential Effect of Four-Week Feeding of Different Dietary Fats on the Accumulation of Fat and the Cholesterol and Triglyceride Contents in the Different Fat Depots. Nutrients, 2020, 12, 3241.	4.1	1
22	A novel GPER antagonist protects against the formation of estrogen-induced cholesterol gallstones in female mice. Journal of Lipid Research, 2020, 61, 767-777.	4.2	13
23	Activation of Estrogen Receptor G Proteinâ€“Coupled Receptor 30 Enhances Cholesterol Cholelithogenesis in Female Mice. Hepatology, 2020, 72, 2077-2089.	7.3	14
24	Novel insights in health-promoting properties of sweet cherries. Journal of Functional Foods, 2020, 69, 103945.	3.4	45
25	Recent Advances in the Critical Role of the Sterol Efflux Transporters ABCG5/G8 in Health and Disease. Advances in Experimental Medicine and Biology, 2020, 1276, 105-136.	1.6	14
26	Physical Activity Modulating Lipid Metabolism in Gallbladder Diseases. Journal of Gastrointestinal and Liver Diseases, 2020, 29, 99-110.	0.9	8
27	The mechanism of dysbiosis in alcoholic liver disease leading to liver cancer. Hepatoma Research, 2020, 2020, .	1.5	21
28	Novel Insights into the Pathogenesis and Management of the Metabolic Syndrome. Pediatric Gastroenterology, Hepatology and Nutrition, 2020, 23, 189.	1.2	128
29	The physical presence of gallstone modulatesex vivocholesterol crystallization pathways of human bile. Gastroenterology Report, 2019, 7, 32-41.	1.3	6
30	Critical Care Aspects of Gallstone Disease. The Journal of Critical Care Medicine, 2019, 5, 6-18.	0.7	18
31	Gastrointestinal defects in gallstone and cholecystectomized patients. European Journal of Clinical Investigation, 2019, 49, e13066.	3.4	14
32	Cholesterol cholelithiasis: part of a systemic metabolic disease, prone to primary prevention. Expert Review of Gastroenterology and Hepatology, 2019, 13, 157-171.	3.0	27
33	Targeting mitochondria to oppose the progression of nonalcoholic fatty liver disease. Biochemical Pharmacology, 2019, 160, 34-45.	4.4	50
34	The Role of Diet in the Pathogenesis of Cholesterol Gallstones. Current Medicinal Chemistry, 2019, 26, 3620-3638.	2.4	66
35	Update on the Molecular Mechanisms Underlying the Effect of Cholecystokinin and Cholecystokinin-1 Receptor on the Formation of Cholesterol Gallstones. Current Medicinal Chemistry, 2019, 26, 3407-3423.	2.4	16
36	Insights into the pharmacology of GPER/GPR30 and its involvement in gallstone formation. FASEB Journal, 2019, 33, 821.1.	0.5	0

#	Article	IF	Citations
37	Silencing steroid receptor coactivator-1 in the nucleus of the solitary tract reduces estrogenic effects on feeding and apolipoprotein A-IV expression. Journal of Biological Chemistry, 2018, 293, 2091-2101.	3.4	7
38	An update on the pathogenesis of cholesterol gallstone disease. Current Opinion in Gastroenterology, 2018, 34, 71-80.	2.3	125
39	Mouse models of gallstone disease. Current Opinion in Gastroenterology, 2018, 34, 59-70.	2.3	29
40	Cholecystectomy: a way forward and back to metabolic syndrome?. Laboratory Investigation, 2018, 98, 4-6.	3.7	18
41	Cholecystectomy and risk of metabolic syndrome. European Journal of Internal Medicine, 2018, 53, 3-11.	2.2	39
42	Similarities and differences between biliary sludge and microlithiasis: Their clinical and pathophysiological significances. Liver Research, 2018, 2, 186-199.	1.4	8
43	Exercising the hepatobiliaryâ€gut axis. The impact of physical activity performance. European Journal of Clinical Investigation, 2018, 48, e12958.	3.4	48
44	Impaired intestinal cholecystokinin secretion, a fascinating but overlooked link between coeliac disease and cholesterol gallstone disease. European Journal of Clinical Investigation, 2017, 47, 328-333.	3.4	12
45	New insights into the role of Lith genes in the formation of cholesterol-supersaturated bile. Liver Research, 2017, 1, 42-53.	1.4	16
46	Transintestinal cholesterol excretion: A secondary, nonbiliary pathway contributing to reverse cholesterol transport. Hepatology, 2017, 66, 1337-1340.	7.3	19
47	Cholesterol and Lipoprotein Metabolism and Atherosclerosis: Recent Advances in Reverse Cholesterol Transport. Annals of Hepatology, 2017, 16, S27-S42.	1.5	172
48	Bile Acid Physiology. Annals of Hepatology, 2017, 16, S4-S14.	1.5	306
49	Cross-Talk Between Bile Acids and Gastro-Intestinal and Thermogenic Hormones: Clues from Bariatric Surgery. Annals of Hepatology, 2017, 16, S68-S82.	1.5	16
50	Bile Acids and Cancer: Direct and Environmental-Dependent Effects. Annals of Hepatology, 2017, 16, S87-S105.	1.5	76
51	BDNF/TrkB signaling mediates the anorectic action of estradiol in the nucleus tractus solitarius. Oncotarget, 2017, 8, 84028-84038.	1.8	11
52	Effect of Inhibition of Intestinal Cholesterol Absorption on the Prevention of Cholesterol Gallstone Formation. Medicinal Chemistry, 2017, 13, 421-429.	1.5	9
53	New Exploration of Chinese Herbal Medicines in Hepatology. Evidence-based Complementary and Alternative Medicine, 2016, 2016, 1-5.	1.2	0
54	Evidence that the adenosine triphosphateâ€binding cassette G5/G8â€independent pathway plays a determinant role in cholesterol gallstone formation in mice. Hepatology, 2016, 64, 853-864.	7.3	21

#	Article	IF	Citations
55	The Biliary System, Second Edition. Colloquium Series on Integrated Systems Physiology From Molecule To Function, 2016, 8, i-178.	0.3	7
56	The cholecystokininâ€1 receptor antagonist devazepide increases cholesterol cholelithogenesis in mice. European Journal of Clinical Investigation, 2016, 46, 158-169.	3.4	11
57	Gallstones. Nature Reviews Disease Primers, 2016, 2, 16024.	30.5	428
58	The dangerous link between childhood and adulthood predictors of obesity and metabolic syndrome. Internal and Emergency Medicine, 2016, 11, 175-182.	2.0	87
59	Apolipoprotein A-V is present in bile and its secretion increases with lipid absorption in Sprague-Dawley rats. American Journal of Physiology - Renal Physiology, 2015, 309, G918-G925.	3.4	8
60	Ginsenoside Rb1 increases insulin sensitivity by activating AMP-activated protein kinase in male rats. Physiological Reports, 2015, 3, e12543.	1.7	37
61	The deletion of the estrogen receptor Î± gene reduces susceptibility to estrogen-induced cholesterol cholelithiasis in female mice. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 2161-2169.	3.8	11
62	Gut vagal afferents are necessary for the eating-suppressive effect of intraperitoneally administered ginsenoside Rb1 in rats. Physiology and Behavior, 2015, 152, 62-67.	2.1	2
63	Estrogen induces two distinct cholesterol crystallization pathways by activating ERÎ± and GPR30 in female mice. Journal of Lipid Research, 2015, 56, 1691-1700.	4.2	38
64	Therapeutic uses of animal biles in traditional Chinese medicine: An ethnopharmacological, biophysical chemical and medicinal review. World Journal of Gastroenterology, 2014, 20, 9952.	3.3	81
65	Cholesterol cholelithiasis in pregnant women: pathogenesis, prevention and treatment. Annals of Hepatology, 2014, 13, 728-745.	1.5	62
66	Estradiol Stimulates Apolipoprotein A-IV Gene Expression in the Nucleus of the Solitary Tract Through Estrogen Receptor-Î±. Endocrinology, 2014, 155, 3882-3890.	2.8	9
67	Obesity and the risk and prognosis of gallstone disease and pancreatitis. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 623-635.	2.4	98
68	Therapeutic Reflections in Cholesterol Homeostasis and Gallstone Disease: A Review. Current Medicinal Chemistry, 2014, 21, 1435-1447.	2.4	19
69	Cholesterol cholelithiasis in pregnant women: pathogenesis, prevention and treatment. Annals of Hepatology, 2014, 13, 728-45.	1.5	19
70	Prevention of cholesterol gallstones by inhibiting hepatic biosynthesis and intestinal absorption of cholesterol. European Journal of Clinical Investigation, 2013, 43, 413-426.	3.4	55
71	Steatosis in the Liver. , 2013, 3, 1493-1532.		33
72	A silybin-phospholipids complex counteracts rat fatty liver degeneration and mitochondrial oxidative changes. World Journal of Gastroenterology, 2013, 19, 3007.	3.3	39

#	Article	IF	Citations
73	The Biliary System. Colloquium Series on Integrated Systems Physiology From Molecule To Function, 2012, 4, 1-148.	0.3	8
74	A Pleiotropic Role for the Orphan Nuclear Receptor Small Heterodimer Partner in Lipid Homeostasis and Metabolic Pathways. Journal of Lipids, 2012, 2012, 1-22.	4.8	32
75	Interactions between Bile Acids and Nuclear Receptors and Their Effects on Lipid Metabolism and Liver Diseases. Journal of Lipids, 2012, 2012, 1-2.	4.8	5
76	Role of mitochondria in nonalcoholic fatty liver disease-from origin to propagation. Clinical Biochemistry, 2012, 45, 610-618.	1.9	108
77	Gallbladder and gastric motility in obese newborns, preâ€adolescents and adults. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1298-1305.	2.8	47
78	Mitochondria in Chronic Liver Disease. Current Drug Targets, 2011, 12, 879-893.	2.1	87
79	Apolipoprotein E reduces food intake via PI3K/Akt signaling pathway in the hypothalamus. Physiology and Behavior, 2011, 105, 124-128.	2.1	20
80	Transgenic overexpression of Abcb11 enhances biliary bile salt outputs, but does not affect cholesterol cholelithogenesis in mice. European Journal of Clinical Investigation, 2010, 40, 541-551.	3.4	16
81	Estradiol Increases the Anorectic Effect of Central Apolipoprotein A-IV. Endocrinology, 2010, 151, 3163-3168.	2.8	24
82	Lith Genes and Genetic Analysis of Cholesterol Gallstone Formation. Gastroenterology Clinics of North America, 2010, 39, 185-207.	2.2	55
83	Effect of gallbladder hypomotility on cholesterol crystallization and growth in CCK-deficient mice. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2010, 1801, 138-146.	2.4	43
84	Effect of ezetimibe on the response of incretin secretion to intestine lipid ingestion. FASEB Journal, 2010, 24, 1009.3.	0.5	0
85	Biliary lipids and cholesterol gallstone disease. Journal of Lipid Research, 2009, 50, S406-S411.	4.2	161
86	Biochemical mechanisms in drug-induced liver injury: Certainties and doubts. World Journal of Gastroenterology, 2009, 15, 4865.	3.3	113
87	New insights into the molecular mechanisms underlying effects of estrogen on cholesterol gallstone formation. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2009, 1791, 1037-1047.	2.4	97
88	Gastrointestinal symptoms and motility disorders in patients with systemic scleroderma. BMC Gastroenterology, 2008, 8, 7.	2.0	55
89	Coordinate regulation of gallbladder motor function in the gut-liver axis. Hepatology, 2008, 47, 2112-2126.	7.3	117
90	Physical chemistry of intestinal absorption of biliary cholesterol in mice. Hepatology, 2008, 48, 177-185.	7.3	20

#	Article	IF	Citations
91	Effect of Ezetimibe on the Prevention and Dissolution of Cholesterol Gallstones. Gastroenterology, 2008, 134, 2101-2110.	1.3	144
92	Molecular pathophysiology and physical chemistry of cholesterol gallstones. Frontiers in Bioscience - Landmark, 2008, 13, 401.	3.0	71
93	Regulation of Intestinal Cholesterol Absorption. Annual Review of Physiology, 2007, 69, 221-248.	13.1	258
94	Quantifying anomalous intestinal sterol uptake, lymphatic transport, and biliary secretion inAbcg8â^'/â^' mice. Hepatology, 2007, 45, 998-1006.	7.3	66
95	Role of intestinal sterol transporters Abcg5, Abcg8, and Npc1l1 in cholesterol absorption in mice: gender and age effects. American Journal of Physiology - Renal Physiology, 2006, 290, G269-G276.	3.4	78
96	Overexpression of estrogen receptor Î± increases hepatic cholesterogenesis, leading to biliary hypersecretion in mice. Journal of Lipid Research, 2006, 47, 778-786.	4.2	53
97	New Insights Into the Genetic Regulation of Intestinal Cholesterol Absorption. Gastroenterology, 2005, 129, 718-734.	1.3	120
98	High cholesterol absorption efficiency and rapid biliary secretion of chylomicron remnant cholesterol enhance cholelithogenesis in gallstone-susceptible mice. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2005, 1733, 90-99.	2.4	53
99	Targeted disruption of the murine cholecystokinin-1 receptor promotes intestinal cholesterol absorption and susceptibility to cholesterol cholelithiasis. Journal of Clinical Investigation, 2004, 114, 521-528.	8.2	88
100	Cholesterol absorption is mainly regulated by the jejunal and ileal ATP-binding cassette sterol efflux transporters Abcg5 and Abcg8 in mice. Journal of Lipid Research, 2004, 45, 1312-1323.	4.2	86
101	Genetic analysis of cholesterol gallstone formation: Searching for Lith (gallstone) genes. Current Gastroenterology Reports, 2004, 6, 140-150.	2.5	65
102	Spontaneous cholecysto- and hepatolithiasis inMdr2?/? mice: A model for low phospholipid-associated cholelithiasis. Hepatology, 2004, 39, 117-128.	7.3	148
103	Estrogen receptor Î±, but not Î², plays a major role in 17Î²-estradiol-induced murine cholesterol gallstones. Gastroenterology, 2004, 127, 239-249.	1.3	68
104	Measurement of intestinal cholesterol absorption by plasma and fecal dual-isotope ratio, mass balance, and lymph fistula methods in the mouse: an analysis of direct versus indirect methodologies. Journal of Lipid Research, 2003, 44, 1042-1059.	4.2	89
105	Feeding natural hydrophilic bile acids inhibits intestinal cholesterol absorption: studies in the gallstone-susceptible mouse. American Journal of Physiology - Renal Physiology, 2003, 285, G494-G502.	3.4	161
106	New concepts of mechanisms of intestinal cholesterol absorption. Annals of Hepatology, 2003, 2, 113-21.	1.5	10
107	Aging per se is an independent risk factor for cholesterol gallstone formation in gallstone susceptible mice. Journal of Lipid Research, 2002, 43, 1950-1959.	4.2	54
108	Effect of Î²-muricholic acid on the prevention and dissolution of cholesterol gallstones in C57L/J mice. Journal of Lipid Research, 2002, 43, 1960-1968.	4.2	50

#	Article	IF	Citations
109	Dietary sphingomyelin suppresses intestinal cholesterol absorption by decreasing thermodynamic activity of cholesterol monomers. Gastroenterology, 2002, 122, 948-956.	1.3	166
110	Susceptibility to murine cholesterol gallstone formation is not affected by partial disruption of the HDL receptor SR-BI. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2002, 1583, 141-150.	2.4	39
111	Genetic factors at the enterocyte level account for variations inintestinal cholesterol absorption efficiency among inbred strains of mice. Journal of Lipid Research, 2001, 42, 1820-1830.	4.2	72
112	Cholic acid aids absorption, biliary secretion, and phase transitions of cholesterol in murine cholelithogenesis. American Journal of Physiology - Renal Physiology, 1999, 276, G751-G760.	3.4	50
113	Phenotypic characterization of Lith genes that determine susceptibility to cholesterol cholelithiasis in inbred mice: pathophysiology of biliary lipid secretion. Journal of Lipid Research, 1999, 40, 2066-2079.	4.2	103
114	Phenotypic characterization of Lith genes that determine susceptibility to cholesterol cholelithiasis in inbred mice: integrated activities of hepatic lipid regulatory enzymes. Journal of Lipid Research, 1999, 40, 2080-2090.	4.2	56
115	No pathophysiologic relationship of soluble biliary proteins to cholesterol crystallization in human bile. Journal of Lipid Research, 1999, 40, 415-425.	4.2	39
116	Sterol carrier protein 2 participates in hypersecretion of biliary cholesterol during gallstone formation in genetically gallstone-susceptible mice. Biochemical Journal, 1998, 336, 33-37.	3.7	60